NO20041855L - Fremgangsmate for behandling av hepatitt C-virusinfeksjon ved behandling av feilpasienter - Google Patents

Fremgangsmate for behandling av hepatitt C-virusinfeksjon ved behandling av feilpasienter

Info

Publication number
NO20041855L
NO20041855L NO20041855A NO20041855A NO20041855L NO 20041855 L NO20041855 L NO 20041855L NO 20041855 A NO20041855 A NO 20041855A NO 20041855 A NO20041855 A NO 20041855A NO 20041855 L NO20041855 L NO 20041855L
Authority
NO
Norway
Prior art keywords
treatment
hepatitis
procedure
virus infection
malignant patients
Prior art date
Application number
NO20041855A
Other languages
English (en)
Inventor
Henry H Hsu
Original Assignee
Intermune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intermune Inc filed Critical Intermune Inc
Publication of NO20041855L publication Critical patent/NO20041855L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20041855A 2001-09-28 2004-04-27 Fremgangsmate for behandling av hepatitt C-virusinfeksjon ved behandling av feilpasienter NO20041855L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32608801P 2001-09-28 2001-09-28
PCT/US2002/030445 WO2003028755A1 (en) 2001-09-28 2002-09-24 Method for treating hepatitis c virus infection in treatment failure patients

Publications (1)

Publication Number Publication Date
NO20041855L true NO20041855L (no) 2004-04-27

Family

ID=23270769

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20041855A NO20041855L (no) 2001-09-28 2004-04-27 Fremgangsmate for behandling av hepatitt C-virusinfeksjon ved behandling av feilpasienter

Country Status (15)

Country Link
US (1) US20050031586A1 (no)
EP (1) EP1435998A4 (no)
JP (1) JP2005508342A (no)
KR (1) KR20040045022A (no)
CN (1) CN1558771A (no)
AR (1) AR036697A1 (no)
BR (1) BR0212917A (no)
CA (1) CA2460589A1 (no)
HU (1) HUP0401657A2 (no)
IL (1) IL160881A0 (no)
MX (1) MXPA04002724A (no)
NO (1) NO20041855L (no)
PL (2) PL369129A1 (no)
WO (1) WO2003028755A1 (no)
ZA (1) ZA200402232B (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007501806A (ja) * 2003-08-13 2007-02-01 ハワード ジェイ． スミス アンド アソシエイツ ピーティーワイ エルティーディー ウィルス感染を治療する方法
US20090246171A1 (en) * 2008-03-27 2009-10-01 Van Antwerp William P Automatic system for dose control in treating hepatitis c using infusion pumps
WO2009120991A2 (en) * 2008-03-27 2009-10-01 Medtronic, Inc. Pharmacokinetic and pharmacodynamic tools to define patient specific therapeutic regimens
RU2011124149A (ru) 2008-11-17 2012-12-27 Ф.Хоффманн-Ля Рош Аг Нафтилуксусные кислоты
EP2459211A1 (en) 2009-07-31 2012-06-06 Medtronic, Inc. Continuous subcutaneous administration of interferon- to hepatitis c infected patients
DE202012012955U1 (de) 2011-10-21 2014-07-14 Abbvie Inc. Eine Kombination aus mindestens zwei direkt wirkenden antiviralen Wirkstoffen (DAAs) für die Verwendung zur Behandlung von HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
EP2583677A3 (en) 2011-10-21 2013-07-03 Abbvie Inc. Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon.
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8470884B2 (en) 2011-11-09 2013-06-25 Hoffmann-La Roche Inc. Alkenyl naphthylacetic acids
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5372808A (en) * 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US5980884A (en) * 1996-02-05 1999-11-09 Amgen, Inc. Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon
US5980554A (en) * 1997-05-05 1999-11-09 Micro Therapeutics, Inc. Wire frame partial flow obstruction for aneurysm treatment
US6172046B1 (en) * 1997-09-21 2001-01-09 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
US6127046A (en) * 1997-12-04 2000-10-03 Cummins Engine Company, Inc. Formation of a graphite-free surface in a ferrous material to produce an improved intermetallic bond

Also Published As

Publication number Publication date
HUP0401657A2 (hu) 2004-11-29
ZA200402232B (en) 2005-03-22
CN1558771A (zh) 2004-12-29
CA2460589A1 (en) 2003-04-10
AR036697A1 (es) 2004-09-29
EP1435998A4 (en) 2005-03-02
PL369129A1 (en) 2005-04-18
MXPA04002724A (es) 2004-07-05
BR0212917A (pt) 2004-12-21
JP2005508342A (ja) 2005-03-31
IL160881A0 (en) 2004-08-31
EP1435998A1 (en) 2004-07-14
WO2003028755A1 (en) 2003-04-10
KR20040045022A (ko) 2004-05-31
US20050031586A1 (en) 2005-02-10
PL368718A1 (en) 2005-04-04

Similar Documents

Publication Publication Date Title
SI1404347T1 (sl) 4'-substituirani nukleozidi za zdravljenje bolezni posredovanih z virusom hepatitisa c
EE05442B1 (et) V„ikeses annuses entekaviiri sisaldav ravimkoostis B-hepatiidi viirusinfektsiooni raviks ning meetod selle valmistamiseks
IL245955B (en) Immunogenic compositions for the prevention and treatment of meningococcal disease
DE60215157D1 (de) Verwendungen von antiviralen nucleosid-derivaten zur herstellung eines medikaments zur behandlung von hepatitis c infektionen
AU2003249977A8 (en) Imidazole compounds for the treatment of hepatitis c virus infections
NO20033684D0 (no) Behandling av motstandsdyktige tumorer ved anvendelse av epotilonderivater
EP1446121A4 (en) DI-INDOLYLMETHANE FOR THE TREATMENT OF INFECTIONS BY HUMAN PAPILLOMAVIRUS
NO20041855L (no) Fremgangsmate for behandling av hepatitt C-virusinfeksjon ved behandling av feilpasienter
EP1357940A4 (en) HEPATITIS? B? VIRUS THERAPY
IL162236A0 (en) Purified hepatitis c virus envelopeproteins for dagnostic and therapeutic use
AU2002219881A1 (en) Methods and compositions for the treatment of human immunodeficiency virus infection
EP1765330A4 (en) PYRANOINDOLE DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF DISEASE OR INFECTION CAUSED BY HEPATITIS C VIRUS
NO20022816D0 (no) Behandling av virale infeksjoner ved anvendelse av Levovirin
NO20033341D0 (no) Metoder for administrering av epothilone-analoger for behandling av kreft
NO20041685L (no) Fremgangsmate for behandling av hepatitt C-virusinfeksjon hos pasienter med manglende behandlingsrespons
IL161138A0 (en) Treatment of hepatitis b virus infection with human monoclonal antibodies
NO20042476L (no) Anvendelse av desoxypeganin for behandling av klinisk depresjon
NO20032769D0 (no) Kombinasjonsmetode for behandling av virale infeksjoner
NO20024325D0 (no) Rensede hepatitt C-viruskappeproteiner for diagnostisk og terapeutisk anvendelse
AU2002327531A1 (en) Therapeutic compositions and methods for treating viral infection
DE60114448D1 (de) Imidazolonderivate zur behandlung viraler krankheiten
NO20022253L (no) Middel til behandling av hepatitt C
AU2003299493A8 (en) Compositions and methods for the treatment of hepatitis c virus infection
NO20042166L (no) Kombinasjonsterapi for behandling av sykdom
HK1078020A (en) Use of cpg oligonucleotides in the treatment of hepatitis c virus infection

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application